### AME Case Series Checklist –Adapted from CARE Checklist and PROCESS Checklist

| Section      | Item | Checklist description                                                                                                                                                                                                 | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|--------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------|
| Title        | 1    | The diagnosis or intervention of primary focus followed by the words “case series”.                                                                                                                                      |                                     |                              |
| Key Words    | 2    | 2 to 5 key words that identify diagnoses or interventions in this case series, including "case report" or "case series".                                                                                                  |                                     |                              |
| Abstract     | 3a   | Introduction—What is unique about this case series and what does it add to the scientific literature?                                                                                                                   |                                     |                              |
|              | 3b   | Methods—describe what was done, how and when was it done and by whom.                                                                                                                                                   |                                     |                              |
|              | 3c   | Results—what was found.                                                                                                                                                                                                  |                                     |                              |
|              | 3d   | Conclusion—What is the main take-away lesson(s)? What have we learned and what does it mean?                                                                                                                             |                                     |                              |
| Introduction | 4    | Explain the scientific background and rationale for the case series.                                                                                                                                                     |                                     |                              |
|              |      | What is the unifying theme - common disease, exposure, intervention and outcome, etc.                                                                                                                                     |                                     |                              |
|              |      | Why is this study needed?                                                                                                                                                                                                |                                     |                              |
| Methods      | 5a   | Registration and ethics—                                                                                                                                                                                                |                                     |                              |
|              |      | 5a.1 State the research registry number in accordance with the declaration of Helsinki - “Every research study involving human subjects must be registered in a publicly accessible database” (this can be obtained from: ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). |                                     |                              |
|              |      | 5a.2 State whether ethical approval was passed.                                                                                                                                                                           |                                     |                              |
|              |      | 5a.3 Provide the patient consent form too.                                                                                                                                                                                |                                     |                              |
|              | 5b   | Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive.                                        |                                     |                              |
|              | 5c   | Setting - describe the setting(s)and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. |                                     |                              |
|              | 5d   | Participants—                                                                                                                                                                                                            |                                     |                              |
|              |      | 5d.1 Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.).                                                                                                 |                                     |                              |
|              |      | 5d.2 State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants.                                                                                                      |                                     |                              |
| 5e | Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5f | Follow up—describe length and methods of follow-up.                                                                                                                                                                                                                     |
| Results | 6a | Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.).                                                                                                                                                        |
| Results | 6b | Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate.                                                                                       |
| Results | 6c | Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up. |
| Results | 6d | Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it.                                                                                                      |
| Results | 6e | Complications and adverse or unanticipated events.                                                                                                                                                                                                                     |
| Discussion | 7a | Summarize key results.                                                                                                                                                                                                                                                  |
| Discussion | 7b | Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible.                                                                                   |
| Discussion | 7c | Strengths and limitations of the study.                                                                                                                                                                                                                              |
| Discussion | 7d | The rationale for any conclusions.                                                                                                                                                                                                                                    |
| Conclusion | 8a | State the key conclusions from the study.                                                                                                                                                                                                                             |
| Conclusion | 8b | State what needs to be done next, further research with what study design.                                                                                                                                                                                              |